Bellicum Pharma (BLCM): Raising PT On Accelerated BPX-501 Approval - Piper Jaffray

Bellicum Pharma (NASDAQ: BLCM) announced a strategy to pursue a rapid path of approval for BPX-501, the company's allogeneic T-cell add-back with an "off switch". The EMA has agreed data that an expanded BP-004 study could support approval under "exceptional circumstances" for pediatric patients in malignant and nonmalignant settings. The analyst e believes BPX-501 is a highly differentiated program and the broad ability to control cells is increasingly attractive in a CAR-T field that has suffered some safety concerns.

The company will also be advancing a CD19 targeting CAR-T with the CaspaCIDe "off-switch" which the analyst believes will be competitive.

Piper Jaffray analyst, Joshua Schimmer, reiterated his Overweight rating but rapid progress of BPX-501 towards approval pushes accelerated EU approval forward into 2018 resulting in a PT change from $25 to $31.

For an analyst ratings summary and ratings history on Bellicum Pharmaceuticals click here. For more ratings news on Bellicum Pharmaceuticals click here.

Shares of Bellicum Pharmaceuticals closed at $17.05 yesterday.

You May Also Be Interested In

• Backblaze Inc (BLZE) PT Raised to $14 at Needham
• Lucid Capital Markets Starts Palmer Square Capital BDC (PSBD) at Neutral
• Nayax (NYAX) PT Raised to $75 at UBS Post Management Meet